Further studies exploring the development of CD8+ TEX in the context of BC neoadjuvant chemotherapy and adjuvant therapy regimens may reveal mechanisms for the survival characteristic differences between patients with ER+ BC and TNBC. This evidence concerns the gene ESR1 and breast cancer.